OBJECTIVE: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). METHOD: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). RESULTS: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. CONCLUSION: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings.
OBJECTIVE: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). METHOD: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). RESULTS: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. CONCLUSION: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings.
Authors: Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman Journal: Am J Hum Genet Date: 2006-03-28 Impact factor: 11.025
Authors: M S Buchsbaum; E Hollander; M M Haznedar; C Tang; J Spiegel-Cohen; T C Wei; A Solimando; B R Buchsbaum; D Robins; C Bienstock; C Cartwright; S Mosovich Journal: Int J Neuropsychopharmacol Date: 2001-06 Impact factor: 5.176
Authors: Juned Siddique; C Hendricks Brown; Donald Hedeker; Naihua Duan; Robert D Gibbons; Jeanne Miranda; Philip W Lavori Journal: Psychiatr Ann Date: 2008-12-01
Authors: Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook Journal: Pharmacogenet Genomics Date: 2015-11 Impact factor: 2.089
Authors: Angela Sagar; Dalila Pinto; Fedra Najjar; Stephen J Guter; Carol Macmillan; Edwin H Cook Journal: Am J Med Genet A Date: 2017-04-13 Impact factor: 2.802
Authors: Fedra Najjar; Thomas Owley; Matthew W Mosconi; Suma Jacob; Kwan Hur; Stephen J Guter; John A Sweeney; Robert D Gibbons; Edwin H Cook; Jeffrey R Bishop Journal: J Child Adolesc Psychopharmacol Date: 2015-08 Impact factor: 2.576
Authors: Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller Journal: Can J Psychiatry Date: 2020-11-23 Impact factor: 5.321